Treating Vision Loss A UCSB team helped create a retinal implant designed to replace support cells damaged by dry age-related macular degeneration By Julie Cohen The trial is ongoing and the team continues to analyze… read more →
In the “wet” type of macular degeneration, abnormal blood vessels (known as choroidalneovascularization or CNV) grow under the retina and macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from… read more →
New research in Phase II clinical trials New drug reduces rate of progression of incurable eye disease by Nicola Webber An international study including researchers from the Centre for Eye Research Australia (CERA) has found… read more →
This is still in the very early stages of research.They have started phase II of the clinical trials. Retinal Pigment Epithelial Transplant Geographic Atrophy By: Michael Johnson, MD – Eastern Maine Medical Center For years,… read more →
This is research is taking place in London, England. It has a long road ahead. Once it comes over to America it will need to go through clinical trails and be approved by the FDA.… read more →
BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD ALAMEDA, Calif.–(Business Wire)–BioTime, Inc., a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical trial… read more →
Shire studies SHP640 for infectious conjunctivitis The first U.S. patient has been enrolled in a phase 3 clinical trial for Shire’s SHP640, a combination broad-spectrum antiseptic and corticosteroid being evaluated for treating infectious keratitis in… read more →
Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema MedicalResearch.com Interview with: Marco A Zarbin, MD, PhD, FACS Alfonse Cinotti, MD/Lions Eye Research Professor and Chair Institute of Ophthalmology & Visual Science Rutgers-New Jersey Medical… read more →
BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its… read more →
A TINY MICROPHONE Measuring blood flow at the back of the eye with a device that can fit in a contact lens could help diagnose AMD and diabetic retinopathy by Selina Powell A transparent device… read more →